GlassScriptPhysician profile
Jennifer E Farren
NPI 1659948057
$8,419.70
in general payments reported to CMS, 2019-2025
22 companies · $1,579 in 2025
The $1,579 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,072 · 2022: $1,535 · 2023: $1,614 · 2024: $2,618 · 2025: $1,579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,805 · Education: $6.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,804.83 |
| Education | $6.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $2,355.30 | 2021-2025 | Gocovri, Gocovri, Apokyn |
| Abbvie INC. | $1,722.42 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,194.19 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $447.96 | 2021-2025 | Ingrezza, Ongentys |
| Acorda Therapeutics, INC | $372.40 | 2021-2024 | Inbrija |
| Acadia Pharmaceuticals INC | $357.17 | 2021-2025 | Nuplazid |
| Amneal Pharmaceuticals LLC | $323.42 | 2021-2025 | Rytary, Crexont |
| Kyowa Kirin, INC. | $284.34 | 2021-2024 | Nourianz |
| Avion Pharmaceuticals | $261.62 | 2022-2023 | Dhivy, Methylphenidate Hydrochloride |
| Medtronic, INC. | $207.82 | 2021-2025 | Sensight |
| Ipsen Biopharmaceuticals, INC | $177.63 | 2025 | Dysport |
| Merz Pharmaceuticals, LLC | $147.48 | 2022-2025 | Xeomin, Inbrija |
| Adamas Pharmaceuticals, INC. | $118.34 | 2021 | |
| Sunovion Pharmaceuticals INC. | $109.35 | 2021-2022 | |
| Boston Scientific Corporation | $101.39 | 2021-2024 | Vercise |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cala Health, INC. | $80.26 | 2025 | Cala Kiq |
| Biogen, INC. | $51.42 | 2024-2025 | Skyclarys |
| Eisai INC. | $39.49 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.82 | 2022 | |
| Mirum Pharmaceuticals, INC. | $19.04 | 2024 | Cholbam |
| Otsuka America Pharmaceutical, INC. | $15.38 | 2024 | Rexulti |
| Grt US Holding, INC. | $13.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Farren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.